Abiopharma

🔍 Hwang Donghyun Thomas (Executive)

Company: MACOM Technology Solutions Holdings, Inc. (MTSI)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Sold 100 shares of Common Stock at $367.3 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 32,276.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 100 shares of Common Stock at $369.99 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 32,176.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 200 shares of Common Stock at $375.34 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 31,976.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 100 shares of Common Stock at $379.8 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 31,876.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 420 shares of Common Stock at $382.04 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 31,456.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 300 shares of Common Stock at $382.91 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 31,156.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 9 shares of Common Stock at $384.35 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 31,147.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 400 shares of Common Stock at $386.62 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,747.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 200 shares of Common Stock at $387.25 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,547.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 400 shares of Common Stock at $388.65 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,147.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 291 shares of Common Stock at $389.74 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 29,856.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 100 shares of Common Stock at $391.94 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 29,756.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The shares were sold pursuant to a sales plan adopted by the Reporting Person on August 11, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $374.86 to $375.82. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $381.55 to $382.47. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $382.80 to $383.04. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $386.18 to $387.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.pon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $387.20 to $387.30. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $388.49 to $388.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $389.57 to $389.86. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.